Cutaneous melanoma, Lancet Lond Engl, vol.383, pp.816-843, 2014. ,
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur J Immunol, vol.31, pp.2007-2022, 2001. ,
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, vol.77, pp.1303-1313, 1996. ,
Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms, Natl Cancer Inst Monogr, vol.44, pp.67-76, 1976. ,
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab, JAMA Dermatol, vol.152, pp.45-51, 2016. ,
The Seiji memorial lecture. Pigment stories: from vitiligo to melanomas and points in between, Pigment Cell Res, vol.2, pp.19-21, 1992. ,
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunol Rev, 2008. ,
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J Exp Med, vol.182, pp.459-65, 1995. ,
T cell exhaustion, Nat Immunol, vol.131, pp.492-501, 2011. ,
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nat Med, vol.12, pp.1198-202, 2006. ,
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, vol.114, pp.1537-1581, 2009. ,
Nivolumab plus Ipilimumab in Advanced Melanoma, N Engl J Med, vol.369, pp.122-155, 2013. ,
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline -Update, European Journal of Cancer, vol.63, pp.201-218, 2016. ,
, The Lancet, vol.392, pp.971-84, 2018.
It is finally time for adjuvant therapy in melanoma, Cancer Treatment Reviews, vol.69, pp.101-112, 2018. ,
Ipilimumab (Yervoy). Highlights of prescribing information ,
Highlights of prescribing information, 2019. ,
Nivolumab (Opdivo). Highlights of prescribing information ,
, Markham A, Duggan S. Cemiplimab: First Global Approval. Drugs, vol.78, pp.1841-1847, 2018.
, , 2011.
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma, Expert Opin Drug Metab Toxicol, vol.12, pp.1247-53, 2016. ,
, , 2015.
An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers, Expert Opin Drug Metab Toxicol, vol.12, pp.1255-61, 2016. ,
, , 2015.
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles, Expert Opin Ther Pat, vol.28, pp.665-78, 2015. ,
Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules, Med Res Rev, vol.39, pp.265-301, 2019. ,
Uveal melanoma as a target for immune-therapy, Ann Transl Med, vol.4, p.172, 2016. ,
Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment, Am Soc Clin Oncol Educ Book, pp.116-138, 2016. ,
Assessing social and economic impact of subcutaneous mAbs in oncology. Glob Reg Health Technol Assess Ital North Eur Span, vol.2018, pp.1-9, 2018. ,
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol, vol.11, pp.155-64, 2010. ,
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma, Br J Clin Pharmacol, vol.78, pp.106-123, 2014. ,
Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, vol.49, pp.493-507, 2010. ,
Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development, BioDrugs Clin Immunother Biopharm Gene Ther, vol.24, pp.23-39, 2010. ,
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors, CPT Pharmacomet Syst Pharmacol, vol.6, pp.49-57, 2017. ,
Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial, CPT Pharmacomet Syst Pharmacol, vol.6, pp.21-29, 2017. ,
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response, J Pharmacokinet Pharmacodyn, vol.44, pp.403-417, 2017. ,
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors: Model-Based Population Pharmacokinetic Analysis of Nivolumab, CPT Pharmacomet Syst Pharmacol, vol.6, pp.58-66, 2017. ,
Association of Time-Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis, Clin Pharmacol Ther, vol.101, pp.657-66, 2017. ,
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, J Transl Med, vol.9, p.204, 2011. ,
Intrapatient Dose Escalation of Anti-CTLA-4 Antibody in Patients With Metastatic Melanoma, J Immunother, vol.29, pp.455-463, 2006. ,
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20), MDX010-20 Investigators, vol.24, pp.2694-2702, 2013. ,
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma, Clin Cancer Res, vol.19, pp.3977-86, 2013. ,
, Phase I Study of Pembrolizumab (MK, p.3475
, Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors, Clin Cancer Res, vol.21, pp.4286-93, 2015.
Alwis DP de. Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example, Clin Cancer Res, vol.22, pp.1318-1342, 2016. ,
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab, CPT Pharmacomet Syst Pharmacol, vol.6, pp.11-20, 2017. ,
Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer. 19th Annu Meet Popul Approach Group Eur, pp.8-11, 2010. ,
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma, CPT Pharmacomet Syst Pharmacol, vol.6, pp.29-39, 2017. ,
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, pp.4103-4111, 2009. ,
The use of tumour volumetrics to assess response to therapy in anticancer clinical trials, Br J Clin Pharmacol, vol.73, pp.846-54, 2012. ,
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, pp.908-926, 2015. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N Engl J Med, vol.372, pp.2521-2553, 2015. ,
Evaluation of dosing strategy for pembrolizumab for oncology indications, J Immunother Cancer, vol.5, p.43, 2017. ,
Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance, Clin Cancer Res, vol.24, issue.23, pp.5841-5849, 2018. ,
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy, J Immunother Cancer, vol.4, p.72, 2016. ,
Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development, Clin Pharmacol Ther, vol.86, pp.167-74, 2009. ,
Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma, CPT Pharmacomet Syst Pharmacol, vol.6, pp.40-48, 2017. ,
Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma, J Clin Pharmacol, vol.57, issue.12, pp.1527-1533, 2017. ,
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, N Engl J Med, vol.372, pp.2006-2023, 2015. ,
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med, vol.373, pp.23-34, 2015. ,
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, Lancet Oncol, vol.18, pp.1202-1212, 2017. ,
A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation, J Clin Oncol, vol.36, pp.3062-3062, 2018. ,
Assessment of nivolumab benefitrisk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann Oncol Off J Eur Soc Med Oncol, vol.28, pp.2002-2010, 2017. ,
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer, Ann Oncol, vol.29, pp.2208-2221, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02143540
Protein breakdown in cancer cachexia, Semin Cell Dev Biol, vol.54, pp.11-20, 2016. ,
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans, Clin Pharmacokinet, vol.58, pp.169-87, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-01821717
, Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet, 2019.
,
Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies, J Clin Oncol, vol.35, pp.14557-14557, 2017. ,
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009. ,
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab ,
, J Clin Oncol, vol.34, pp.1510-1517, 2016.
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials, Eur J Cancer, vol.74, pp.89-95, 2017. ,
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, vol.359, issue.6371, p.97, 2017. ,